Stephan Michels

Learn More
PURPOSE To evaluate an optical coherence tomography (OCT)-guided, variable-dosing regimen with intravitreal ranibizumab for the treatment of patients with neovascular age-related macular degeneration (AMD). DESIGN Open-label, prospective, single-center, nonrandomized, investigator-sponsored clinical study. METHODS In this two-year study, neovascular AMD(More)
PURPOSE To evaluate the short-term safety of systemic bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA) and its effects on visual acuity (VA) and subfoveal choroidal neovascularization (CNV) in patients with neovascular age-related macular degeneration (AMD). DESIGN Open-label, single-center, uncontrolled clinical study. PARTICIPANTS(More)
PURPOSE To evaluate the effect of photodynamic therapy (PDT) on perfusion and vascular integrity of choroidal neovascularization (CNV) and collateral physiological choroid. METHODS In a prospective clinical trial, patients with subfoveal CNV were treated with PDT and verteporfin. Indocyanine green angiography (ICG-A), using a confocal laser scanning(More)
PURPOSE To evaluate the impact of photodynamic therapy (PDT) on expression and distribution of vascular endothelial growth factor (VEGF), VEGF receptor (VEGFR)-3, and pigment epithelium-derived factor (PEDF). METHODS Eyes of patients scheduled for enucleation due to untreatable malignancy served as study eyes (n = 4), age-matched donor eyes were used as(More)
PURPOSE Neovascular age-related macular degeneration (AMD) resulting in decreased central vision severely impairs affected individuals. Current standard treatment is an intravitreal anti-VEGF therapy (ranibizumab), but responses to treatment show large variability. Genetic factors that influence AMD and that affect the outcome of ranibizumab treatment were(More)
OBJECTIVE To document the anatomic and functional outcome of photodynamic therapy (PDT) in symptomatic choroidal hemangioma DESIGN Prospective, noncomparative, interventional case series. PARTICIPANTS Fifteen patients with circumscribed choroidal hemangioma of the posterior pole presenting with progressive vision loss caused by exudation into the(More)
PURPOSE To improve selectivity of verteporfin therapy (PDT) in neovascular age-related macular degeneration (AMD) using modified treatment parameters. METHODS Nineteen consecutive patients with predominantly classic choroidal neovascularization (CNV) in AMD were treated with 6 mg/m2 verteporfin given as bolus infusion. Patients received PDT with a fluence(More)
PURPOSE To evaluate the safety, efficacy, and durability of bevacizumab for the treatment of subfoveal choroidal neovascularization (CNV) in patients with neovascular age-related macular degeneration (AMD). DESIGN Open-label, single-center, uncontrolled clinical study. PARTICIPANTS Age-related macular degeneration patients with subfoveal CNV (n = 18)(More)
PURPOSE To demonstrate a new generation of three-dimensional (3-D) ultrahigh-resolution optical coherence tomography (UHR OCT) technology for visualization of macular diseases. METHODS One hundred forty eyes with a distinct disease in each of the posterior pole compartments were examined with 3-D UHR OCT. 3-D imaging was performed with a high axial(More)
PURPOSE To identify early vascular changes in choroidal neovascularization (CNV) and in adjacent normal choroid, after photodynamic therapy (PDT). METHODS In a prospective study, 40 patients with predominantly classic CNV due to age-related macular degeneration (AMD) were treated with PDT performed with verteporfin. Verteporfin was administered(More)